AMGN

Amgen Inc. Common Stock

Nasdaq Global Select

$216.07

Open: $217.09 High: $219.85 Low: $214.275 Close: $216.12

Range: 2021-09-20 - 2021-09-21

Volume:4,139,232

Market: Open

Get Free API Key

Download as Excel

AMGN

Amgen Inc. Common Stock One Amgen Center Drive Thousand Oaks CA, 91320-1799 http://www.amgen.com

Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.

CEO: Robert A. Bradway
Employees: 20,800
Sector: Healthcare
Industry: Biotechnology

Latest Stocks Posts

View All Posts >

AMGN News

Latest news about the AMGN

Amgen Wins Patent Case on Otezla® (apremilast)
Amgen today announced that the U.S. District Court for the District of New Jersey has upheld patents that protect Amgen's psoriasis therapy Otezla® (apremilast) in a patent infringement lawsuit against Sandoz Inc. ("Sandoz") and Zydus Pharmaceuticals (USA), Inc. ("Zydus"). The asserted patents claim apremilast as a composition of matter ("COM"), methods of treating psoriasis with apremilast, and crystalline forms of apremilast. The court found infringement and upheld the validity of four patents
View More →
Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer
Mirati could beat Amgen to market with a KRAS-blocking colon cancer drug, an analyst said Monday as MRTX stock popped.
View More →
Why Verastem Stock Spiked Today
A clinical collaboration with biotech titan Amgen briefly lit a fire underneath Verastem's shares today.
View More →
Mirati drug combination shrinks tumors in 39% of colon cancer patients in study
A combination of Mirati Therapeutics Inc's genetic mutation-targeting adagrasib and older cancer drug Erbitux shrank tumors in 39% of patients with advanced colorectal cancer treated in a small trial, the company said on Sunday. Chief Executive Officer Charles Baum told Reuters Mirati plans to meet with the U.S. Food and Drug Administration in October to discuss whether it can pursue accelerated approval based on the combination therapy data. Adagrasib targets a mutated form of a gene known as KRAS that occurs in around 13% of non-small cell lung cancers, 3% to 5% of colorectal cancers and up to 2% of other solid tumor cancers.
View More →
Boasting A 70% Return On Equity, Is Amgen Inc. (NASDAQ:AMGN) A Top Quality Stock?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
View More →
Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer
Amgen Inc (NASDAQ: AMGN) announced data from a Phase 1b/2 study evaluating the combination of Lumakras (sotorasib) with Vectibix (panitumumab) in patients with KRAS G12C-mutated advanced colorectal cancer. Related Link: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer. The data showed that the combination therapy led to improved response rates. The results were detailed at the European Society for Medical Oncology (ESMO21) congress. Findings from the study showed
View More →
LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Amgen (NASDAQ: AMGN) today announced the first combination study results from the Phase 1b/2 CodeBreaK 101 study, the most comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer (CRC). These new data show that combining LUMAKRAS™ (sotorasib) with Vectibix® (panitumumab), Amgen's monoclonal antibody epidermal growth factor receptor (EGFR) inhibitor, demonstrated encouraging efficacy and safety. Overall, the objective response rate (ORR) was
View More →
Amgen And The Lundquist Institute Announce That Diadem Therapeuctics Will Receive The First Amgen Golden Ticket To BioLabs LA
Amgen (NASDAQ: AMGN) and The Lundquist Institute today announced that Diadem Biotherapeutics, Inc., has been awarded the first Amgen Golden Ticket in Southern California. Diadem will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen's scientific and business leaders.
View More →
Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference
Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:45 a.m. ET on Friday, Sept. 17, 2021. Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
View More →
Amgen To Webcast Investor Call At ESMO 2021
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2021 Congress. On Thursday, Sept. 16, 2021, at 8:30 a.m. ET, David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with other members of Amgen's management team, will discuss clinical data being presented on the Company's KRASG12C inhibitor LUMAKRAS™ (sotorasib) in combination with Vectibix® (panitumumab).
View More →
Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021
Amgen (NASDAQ: AMGN) today announced that new data from its expanding inflammation pipeline and marketed portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress, which will take place virtually Sept. 29 – Oct. 2.
View More →
These Promising Clinical Results Could Be Huge for Amgen Investors
New data from the phase 3 trial of tezepelumab bodes well for the drug candidate becoming a significant revenue producer in the near future.
View More →
Lung cancer patients in England to receive Amgen drug that targets a gene mutation
Lung cancer patients in England will become the first in Europe to receive a drug made by U.S. biotech Amgen Inc that targets a specific gene mutation, the country's health service said on Friday. NHS England said it was fast-tracking lung cancer drug sotorasib after it was shown in clinical trials to stop lung cancer progression for seven months. The drug, taken as a tablet, will be used on patients with the KRAS G12C mutation that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer.
View More →
Amgen to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 19th Annual Global Healthcare Conference at 2:45 p.m. ET on Tuesday, Sept. 14, 2021. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
View More →
Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients
Amgen Inc (NASDAQ: AMGN) announced results from two analyses of the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib). Lumakras, a KRASG12C inhibitor, is approved in the U.S. for previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). Related Content: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer. In a post-hoc analysis of 40 patients, Lumakras achieved a 77.5% disease control rate (DCR), similar
View More →
Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?
Everyone likes a bargain, and buying stocks "on sale" is particularly alluring when the companies hitting a rough patch have familiar names, such as those in the Dow Jones Industrial Average. The index is up by about 16%, but the three laggards' stock performance is in negative territory. With that caveat in mind, it's time to examine this year's worst-performing companies in the Dow Jones Industrial Average to see if these are value stocks or if their troubles have only begun.
View More →
Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21
Amgen (NASDAQ: AMGN) today announced results from two analyses of the Phase 2 CodeBreaK 100 clinical trial evaluating LUMAKRAS™ (sotorasib), the first and only KRASG12C inhibitor approved in the U.S., in the treatment of previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). These new analyses, respectively, provide encouraging evidence of durable systemic anticancer activity in patients with previously treated, stable brain metastases with
View More →
3 Beaten-Up Stocks for Bargain Hunters
Three stocks that have been falling in recent weeks that could be great buys today are Amgen (NASDAQ: AMGN), Alibaba Group Holdings (NYSE: BABA), and Dollar Tree (NASDAQ: DLTR). Drugmaker Amgen is a relatively cheap stock to own today, trading at a price-to-earnings (P/E) multiple of 23 (the average stock in the Health Care Select Sector SPDR Fund is trading at 27 times its profits). During the first three months of the year, Amgen's revenue of $5.9 billion declined 4% year over year; the company blamed the poor results on the pandemic and patient visits being down.
View More →
US STOCKS-S&P 500 ends down, Big Tech lifts Nasdaq to record
The S&P 500 closed lower on Tuesday while the Nasdaq edged up to a record high, as investors balanced worries about the slowing pace of economic recovery with expectations that the Federal Reserve will maintain its accommodative monetary policy. Amgen Inc fell 2.1% and Merck & Co lost 1.6% after Morgan Stanley cut its rating on the stocks to "equal-weight" from "overweight."
View More →
US STOCKS-Big Tech fuels Nasdaq record, S&P 500 dips
The S&P 500 fell on Tuesday while the Nasdaq hit a record high, as investors balanced worries about the slowing pace of economic recovery with expectations that the Federal Reserve will maintain its accommodative monetary policy. Amgen Inc dropped 2.3% and Merck & Co fell 1.6% after Morgan Stanley cut its rating on the stocks to "equal-weight" from "overweight".
View More →

AMGN

AMGN

Amgen Inc. Common Stock One Amgen Center Drive Thousand Oaks CA, 91320-1799 http://www.amgen.com

Latest Stocks Posts

View All Posts >

AMGN News

Latest news about the AMGN

Request a consultation.

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader

AMGN

AMGN

Amgen Inc. Common Stock One Amgen Center Drive Thousand Oaks CA, 91320-1799 http://www.amgen.com

Share AMGN Stock Page

Latest Stocks Posts

View All Posts >

AMGN News

Latest news about the AMGN

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader